Bedrijfsoverzicht
Abpro Corporation is a biotechnology enterprise dedicated to the development of novel antibody constructs specifically for applications in immuno-oncology and ophthalmology. The company's strategic platforms include DiversImmune, which functions as a discovery mechanism to generate a diverse collection of proprietary antibodies against clinically validated and novel targets, alongside its MultiM platform. Operating within the broader Healthcare sector and the specialized Biotechnology industry, the firm targets high-value therapeutic areas where proprietary intellectual property can yield significant long-term value. The company currently maintains a market capitalization of $1.42M and employs a workforce of 6 individuals, reflecting an extremely lean operational structure typical of early-stage biotech ventures. The combination of a market cap under $2 million and zero reported annual revenue indicates that Abpro Corporation is in a pre-commercialization phase, relying entirely on external capital to fund research and development before achieving product revenue.
Financiële gezondheid
The financial statements for the trailing twelve months reveal a revenue of $0, a net income of -$22,040,000, and an EBITDA of -$9,301,000, highlighting a significant divergence between top-line activity and bottom-line profitability. The substantial gap between the zero revenue and the negative net income of over $22 million reveals a cost structure dominated by heavy research expenditures and operational burn rates rather than sales-driven expenses. Despite the negative earnings, the company reports a free cash flow of $6.37M, which suggests a strong balance sheet liquidity position capable of funding operations without immediate external financing. This positive free cash flow provides the company with essential financial flexibility to sustain its R&D pipeline and cover ongoing overhead costs during the development lifecycle. The gross margin stands at 0.0%, the operating margin is 0.0%, and the profit margin is 0.0%, indicating that the company has not yet generated any profitable sales to offset its fixed and variable costs. On the liability side, the company holds $328,000 in cash against $147,000 in debt, resulting in a debt-to-equity ratio of N/A due to the lack of equity value in the traditional sense. The current ratio is calculated at 0.07, which indicates a severe liquidity constraint where current liabilities significantly exceed current assets, posing a risk for short-term solvency. Furthermore, the return on equity is N/A because there is no tangible book value to measure against, while the return on assets is -229.6%, revealing that the asset base is currently generating substantial losses relative to its value.
Waarderingsbeoordeling
Valuation multiples for Abpro Corporation are unavailable in traditional terms, with the trailing P/E ratio listed as N/A and the forward P/E also listed as N/A, which implies that earnings per share are not positive enough to support a standard price-to-earnings calculation. The price-to-book ratio is recorded at -0.09, a negative figure that indicates the market is valuing the company at a discount relative to its book value, often seen in distressed or unprofitable biotech firms. The price-to-sales ratio is listed as inf, reflecting the absence of sales revenue in the denominator, while the EV/EBITDA stands at -0.19, suggesting the enterprise value is negative relative to earnings before interest, taxes, depreciation, and amortization. Regarding stock price metrics, the 52-week high is $18.03 and the 52-week low is $0.11, placing the current trading environment within a highly volatile range defined by these extremes. The beta value is -0.00, which is an anomalous statistic for an equity instrument and suggests that the stock price movement has no correlation with the broader market index.
Growth & Income
The revenue growth year-over-year is N/A and the earnings growth year-over-year is N/A, as the company has not yet established a consistent historical revenue stream to calculate growth rates. Since the company does not pay dividends, the dividend yield is N/A and the payout ratio is 0.0%, indicating that all available cash flow is retained within the company to fund operations and R&D rather than being distributed to shareholders. The absence of a dividend policy aligns with the typical lifecycle of a biotechnology firm that reinvests all earnings and cash reserves into advancing its immuno-oncology and ophthalmology platforms. Consequently, the overall growth and income profile of Abpro Corporation is characterized by a complete lack of current income generation and undefined historical growth metrics, relying solely on future potential rather than current financial performance.